Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LUMIADE-3: FKS518 vs Prolia in Postmenopausal Osteoporosis
2020-004422-31Phase 3Completed
- Sponsor
- Fresenius Kabi
- Start
- Dec 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of denosumab in osteoporosis (2 arms), sponsored by Fresenius Kabi. Primary endpoint: Primary efficacy endpoint (equivalence in efficacy between FKS518 and US-Prolia). Started Dec 2020; status: completed.
02
Drugs
denosumab
03
Conditions
osteoporosis
Beyond the preview
Go deeper on 2020-004422-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-004422-31.